Novartis Venture Fund and Sanofi Ventures are among the four investors that co-led Expansion Therapeutics' $55.3m series A round.

Restorbio, an aging-related disease drug developer co-founded by PureTech Health, also counts Novartis as a shareholder.

Purdue University-linked companies operating the in renewable energy, sustainable transport and oncology sectors are among those to have secured $20,000 in initial funding.

GV and Celgene-backed Armo BioSciences has filed to raise up to $86.3m in an offering that will fund clinical tests for its lead immuno-oncology candidate.

Novartis participated in a series B round that raised $50m for Pear Therapeutics, the creator of a software platform that assists substance abuse treatment.

Corporate venturing unit Bloomberg Beta has exited app testing platform developer BuddyBuild through an acquisition of undisclosed size by Apple.

Microsoft joined a consortium including existing investors GV and WuXi NextCode to take the biomedical data platform's overall financing to $105m.

Johns Hopkins University spinout NexImmune has raised series A funding a year after being acquired by a consortium of individual investors in January 2017.

The Novo and Merck-backed pruritus therapy developer has filed to raise up to $97.8m, having already secured almost $110m in VC funding.